소라페닙 치료 실패 후 세포독성화학요법으로 완전반응을 보인 폐전이를 동반한 간세포암 1예
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박화선 | - |
dc.contributor.author | 장재영 | - |
dc.contributor.author | 백민영 | - |
dc.contributor.author | 김용권 | - |
dc.contributor.author | 윤현진 | - |
dc.contributor.author | 백수영 | - |
dc.contributor.author | 정승원 | - |
dc.contributor.author | 이세환 | - |
dc.contributor.author | 김상균 | - |
dc.contributor.author | 차상우 | - |
dc.contributor.author | 김영석 | - |
dc.contributor.author | 조영덕 | - |
dc.contributor.author | 김홍수 | - |
dc.contributor.author | 김부성 | - |
dc.date.accessioned | 2021-08-11T16:24:05Z | - |
dc.date.available | 2021-08-11T16:24:05Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.issn | 2383-5001 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8318 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the 2nd most common cause of cancer related death in Korea and well-known malignancy with poor prognosis. Sorafenib is the first-line molecular targeted agent in patients with extra-hepatic spread of HCC. However, complete response is extremely rare in patients treated with sorafenib and the disease control rate is only 43%. We report a 53-year-old man with advanced HCC with pulmonary metastasis who showed complete response by cytotoxic chemotherapy with doxorubicin and cisplatin with relatively tolerable adverse effects after failure of treatment with sorafenib. (J Liver Cancer 2017;17:72-76) | - |
dc.format.extent | 5 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한간암학회 | - |
dc.title | 소라페닙 치료 실패 후 세포독성화학요법으로 완전반응을 보인 폐전이를 동반한 간세포암 1예 | - |
dc.title.alternative | A Case of Hepatocellular Carcinoma with Pulmonary Metastasis Who Showed Complete Response by Cytotoxic Chemotherapy after Sorafenib Failure | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | 대한간암학회지, v.17, no.1, pp 72 - 76 | - |
dc.citation.title | 대한간암학회지 | - |
dc.citation.volume | 17 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 72 | - |
dc.citation.endPage | 76 | - |
dc.identifier.kciid | ART002208257 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Pulmonary metastasis | - |
dc.subject.keywordAuthor | Cytotoxic chemotherapy | - |
dc.subject.keywordAuthor | Sorafenib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.